Search Results
33 Results Found for “Spanish”
In this Future Leaders interview, Dr Gómez Rivas discusses the mentors who shaped his career, the values that sustain a life in surgery and research, and the importance of mentorship, teamwork and resilience for the next generation of urologists.
As President of the European Cancer Organisation, Dr Isabel Rubio is leading Europe’s fight against cancer with a clear vision: sustained investment, stronger coordination, and measurable progress. From groundbreaking research to policy innovation, she is driving change where it matters most – for patients. In this Q&A with touchONCOLOGY, Dr Rubio explains her priorities for shaping Europe’s cancer landscape over the next two years.
Cancer nursing is central to delivering complex, evidence-based cancer care across Europe. To meet evolving needs, the EONS Education Working Group develops frameworks, training, networks, and safety initiatives. These efforts advance professional growth, strengthen education, and shape the future of cancer nursing—ultimately improving outcomes for patients and families.
July is Sarcoma Awareness Month, with a 2025 focus on supporting healthcare professionals in recognising early signs. Dr Rodrigo Munhoz shares key insights from ASCO 2025, where data highlighted how immune and targeted therapies, along with synergistic strategies, are reshaping sarcoma treatment and driving progress across diverse histologies.
"A mentor once told me to always stay true to my values – advice that has guided me throughout my career" Dr Eric Lander (Director of Research at Minnesota Oncology – Minneapolis, MN, USA) shares his journey and insights into the ...
The phase III PRIMA/ENGOT-OV26/GOG-3012 trial evaluated the efficacy of niraparib as a first-line maintenance treatment for patients with advanced ovarian cancer who responded to platinum-based chemotherapy. In this final analysis, no significant difference in overall survival was observed ...
In the latest edition of touchREVIEWS in Oncology & Haematology, we are pleased to present a collection of articles that delve into the latest research and advancements in the field. From innovative therapies and genetic treatments to analyses of digital ...
Breast cancer is the leading cause of cancer death in Hispanic women in the USA. According to the American Cancer Society, as many as one in nine Hispanic women will develop invasive breast cancer during their lifetime and one in 49 ...
Acute lymphoblastic leukaemia (ALL) is a group of malignant haematological disorders characterised by accumulation of lymphoid cell precursors that replace normal bone marrow elements and inhibit the production of functional blood cells.1Â ALL occurs in both children and adults, and ...
In an exciting landscape where treatment is moving towards personalised medicine, leading multiple myeloma specialist Maria Victoria Mateos shares her updates and highlights for the year ahead. Q. What are the biggest challenges you face when treating patients with multiple ...
Smoldering myeloma is an asymptomatic clonal plasma cell disorder that is characterized by the presence of ≥3 g/dl serum M-protein and/or 10–59% bone marrow plasma cell infiltration, and is a precursor stage to multiple myeloma.1 Historically, patients with smoldering myeloma ...
Myelodysplastic syndrome (MDS) is a cytogenetic, epigenetic, and immunological heterogeneous group of myeloid disorders characterized by dysplastic hematopoeisis and propensity for acute myelogenous leukemia (AML) transformation.1,2 The Surveillance, Epidemiology, and End Results (SEER) Program estimates that risk factors for the ...
While the incidence of primary breast cancer has increased recently, most patients are diagnosed with early-stage disease and good prognosis. Around 80 % of patients with early breast cancer have estrogen receptor (ER)-positive disease and their prognosis will be improved substantially ...
Multiple myeloma (MM) is an incurable plasma cell disease that comprises 1 % of all cancers and 10 % of hematologic malignancies. It primarily affects older individuals—the median age at the moment of diagnosis is 70 years—and two-thirds of multiple myeloma patients are ...
Multiple myeloma (MM) is an incurable plasma cell disease that comprises 1 % of all cancers and 10 % of hematologic malignancies. It primarily affects older individuals—the median age at the moment of diagnosis is 70 years—and two-thirds of multiple myeloma patients are ...
Overview of Registration Trials Data in Urothelial Carcinoma In total, 450 patients were treated in two phase II trials and one phase III trial that together formed the basis for the registration of vinflunine monotherapy in urothelial carcinoma patients after failure ...
An increasing proportion of elderly people attend medical oncology consultations in which many questions about appropriate treatment will be raised by the oncologist. The balance between treatment benefits (in terms of further life expectancy of the elderly) and risks (hematologic ...
Myelodysplastic Syndromes (MDS) are a heterogeneous group of clonal hematopoietic stem cell diseases characterized by morphologic changes in the bone marrow, peripheral cytopenia(s), and susceptibility to bone marrow failure with or without progression to Acute Myeloid Leukemia (AML). Although ...
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
